Annals of Epidemiology
Volume 16, Issue 2 , Pages 105-112 , February 2006

Sex Hormone-Binding Globulin and Serum Testosterone are Inversely Associated with C-Reactive Protein Levels in Postmenopausal Women at High Risk for Cardiovascular Disease

Received 22 April 2005 ,Accepted 19 July 2005.

References 

  1. Ridker PM. Clinical application of C–reactive protein for cardiovascular disease detection and prevention. Circulation. 2003;107:363–369
  2. Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med. 1999;340:115–126
  3. Bernini GP, Sgro M, Moretti A, Argenio GF, Barlascini CO, Cristofani R, et al. Endogenous androgens and carotid intimal-medial thickness in women. J Clin Endocrinol Metab. 1999;84:2008–2012
  4. Reinecke H, Bogdanski J, Woltering A, Breithardt G, Assmann G, Kerber S, et al. Relation of serum levels of sex hormone binding globulin to coronary heart disease in postmenopausal women. Am J Cardiol. 2002;90:364–368
  5. Lapidus L, Lindstedt G, Lundberg PA, Bengtsson C, Gredmark T. Concentrations of sex–hormone binding globulin and corticosteroid binding globulin in serum in relation to cardiovascular risk factors and to 12–year incidence of cardiovascular disease and overall mortality in postmenopausal women. Clin Chem. 1986;32:146–152
  6. Haffner SM, Moss SE, Klein BE, Klein R. Sex hormones and DHEA–SO4 in relation to ischemic heart disease mortality in diabetic subjects. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. Diabetes Care. 1996;19:1045–1050
  7. Phillips GB, Jing TY, Laragh JH. Serum sex hormone levels in postmenopausal women with hypertension. J Hum Hypertens. 1997;11:523–526
  8. Oh JY, Barrett-Connor E, Wedick NM, Wingard DL. Endogenous sex hormones and the development of type 2 diabetes in older men and women: The Rancho Bernardo Study. Diabetes Care. 2002;25:55–60
  9. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med. 1999;340:1801–1811
  10. Laaksonen DE, Niskanen L, Punnonen K, Nyyssonen K, Tuomainen TP, Salonen R, et al. Sex hormones, inflammation and the metabolic syndrome: A population-based study. Eur J Endocrinol. 2003;149:601–608
  11. Kelly CC, Lyall H, Petrie JR, Gould GW, Connell JM, Sattar N. Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab. 2001;86:2453–2455
  12. Kaczmarek A, Reczuch K, Majda J, Banasiak W, Ponikowski P. The association of lower testosterone level with coronary artery disease in postmenopausal women. Int J Cardiol. 2003;87:53–57
  13. Blum CA, Muller B, Huber P, Kraenzlin M, Schindler C, De Geyter C, et al. Low-grade inflammation and estimates of insulin resistance during the menstrual cycle in lean and overweight women. J Clin Endocrinol Metab. 2005;90:3230–3235
  14. Buring JE, Hennekens C. The Women's Health Study: summary of the study design. J Myocardial Ischemia. 1992;4:27–29
  15. Hankinson SE, Manson JE, Spiegelman D, Willett WC, Longcope C, Speizer FE. Reproducibility of plasma hormone levels in postmenopausal women over a 2–3–year period. Cancer Epidemiol Biomarkers Prev. 1995;4:649–654
  16. Wu CH, Lundy LE. Radioimmunoassay of plasma estrogens. Steroids. 1971;18:91–111
  17. Selby C. Sex hormone binding globulin: Origin, function and clinical significance. Ann Clin Biochem. 1990;27(Pt 6):532–541
  18. Miller KK, Rosner W, Lee H, Hier J, Sesmilo G, Schoenfeld D, et al. Measurement of free testosterone in normal women and women with androgen deficiency: Comparison of methods. J Clin Endocrinol Metab. 2004;89:525–533
  19. Decensi A, Omodei U, Robertson C, Bonanni B, Guerrieri–Gonzaga A, Ramazzotto F, et al. Effect of transdermal estradiol and oral conjugated estrogen on C-reactive protein in retinoid-placebo trial in healthy women. Circulation. 2002;106:1224–1228
  20. Modena MG, Bursi F, Fantini G, Cagnacci A, Carbonieri A, Fortuna A, et al. Effects of hormone replacement therapy on C-reactive protein levels in healthy postmenopausal women: Comparison between oral and transdermal administration of estrogen. Am J Med. 2002;113:331–334
  21. Ridker PM, Hennekens CH, Rifai N, Buring JE, Manson JE. Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation. 1999;100:713–716
  22. Stomati M, Hartmann B, Spinetti A, Mailand D, Rubino S, Albrecht A, et al. Effects of hormonal replacement therapy on plasma sex hormone-binding globulin, androgen and insulin-like growth factor-1 levels in postmenopausal women. J Endocrinol Invest. 1996;19:535–541
  23. Mathur RS, Landgrebe SC, Moody LO, Semmens JP, Williamson HO. The effect of estrogen treatment on plasma concentrations of steroid hormones, gonadotropins, prolactin and sex hormone-binding globulin in post-menopausal women. Maturitas. 1985;7:129–133
  24. Lukanova A, Lundin E, Zeleniuch–Jacquotte A, Muti P, Mure A, Rinaldi S, et al. Body mass index, circulating levels of sex-steroid hormones, IGF-I and IGF-binding protein-3: A cross-sectional study in healthy women. Eur J Endocrinol. 2004;150:161–171
  25. Obesity: Preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser. 2000;894:i–xii1–253
  26. Goodman-Gruen D, Barrett-Connor E. A prospective study of sex hormone-binding globulin and fatal cardiovascular disease in Rancho Bernardo men and women. J Clin Endocrinol Metab. 1996;81:2999–3003
  27. Phillips GB, Pinkernell BH, Jing TY. Relationship between serum sex hormones and coronary artery disease in postmenopausal women. Arterioscler Thromb Vasc Biol. 1997;17:695–701
  28. Rexrode KM, Manson JE, Lee IM, Ridker PM, Sluss PM, Cook NR, et al. Sex hormone levels and risk of cardiovascular events in postmenopausal women. Circulation. 2003;108:1688–1693
  29. Joseph DR. Sequence and functional relationships between androgen-binding protein/sex hormone-binding globulin and its homologs protein S, Gas6, laminin, and agrin. Steroids. 1997;62:578–588
  30. Nakano T, Higashino K, Kikuchi N, Kishino J, Nomura K, Fujita H, et al. Vascular smooth muscle cell-derived, Gla-containing growth-potentiating factor for Ca(2+)-mobilizing growth factors. J Biol Chem. 1995;270:5702–5705
  31. Chen J, Carey K, Godowski PJ. Identification of Gas6 as a ligand for Mer, a neural cell adhesion molecule related receptor tyrosine kinase implicated in cellular transformation. Oncogene. 1997;14:2033–2039
  32. Merrill JT, Lahita RG. Sex hormone binding globulins and atherosclerotic risk in systemic lupus. Lupus. 2000;9:217–222
  33. Haffner SM, Dunn JF, Katz MS. Relationship of sex hormone-binding globulin to lipid, lipoprotein, glucose, and insulin concentrations in postmenopausal women. Metabolism. 1992;41:278–284
  34. Jayagopal V, Kilpatrick ES, Jennings PE, Hepburn DA, Atkin SL. The biological variation of testosterone and sex hormone-binding globulin (SHBG) in polycystic ovarian syndrome: Implications for SHBG as a surrogate marker of insulin resistance. J Clin Endocrinol Metab. 2003;88:1528–1533
  35. Rexrode KM, Pradhan A, Manson JE, Buring JE, Ridker PM. Relationship of total and abdominal adiposity with CRP and IL-6 in women. Ann Epidemiol. 2003;13:674–682
  36. Golden SH, Maguire A, Ding J, Crouse JR, Cauley JA, Zacur H, et al. Endogenous postmenopausal hormones and carotid atherosclerosis: A case-control study of the atherosclerosis risk in communities cohort. Am J Epidemiol. 2002;155:437–445
  37. Barrett-Connor E, Goodman-Gruen D. Prospective study of endogenous sex hormones and fatal cardiovascular disease in postmenopausal women. Bmj. 1995;311:1193–1196
  38. Vehkavaara S, Silveira A, Hakala-Ala-Pietila T, Virkamaki A, Hovatta O, Hamsten A, et al. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women. Thromb Haemost. 2001;85:619–625

 This work was supported by the Doris Duke Charitable Foundation.

PII: S1047-2797(05)00267-X

doi: 10.1016/j.annepidem.2005.07.055

Annals of Epidemiology
Volume 16, Issue 2 , Pages 105-112 , February 2006

Article Tools

* Image Usage & Resolution